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Abstract
Objective: We studied whether the severity of GH deficiency (GHD) defined as i) GH-peak on stimulation
tests (insulin tolerance test (ITT), arginine, and glucagon), ii) number of additional pituitary deficits,
or iii) baseline IGF1 SDS could impact the response to GH treatment. We further explored whether
iv) IGF1 SDS after 24 months of GH replacement or v) DIGF1 SDS from baseline to 24 months was
related to the phenotypic response to GH treatment.
Design, patients, and measurements: The patient cohort (nZ1752; 50% women) was obtained from
KIMS (Pfizer International Metabolic Database). The patients were divided into three groups of
approximately equal size (tertiles) according to the stimulated GH-peak values and baseline IGF1 SDS
and were studied at baseline, 12, and 24 months of GH therapy.
Results: Lower baseline IGF1 SDS predicted better response in weight, BMI, total cholesterol, and
triglycerides, while IGF1 SDS after 24 months was associated with reduction in waist/hip ratio, total
cholesterol, and improved quality of life (QoL). Age-correlated negatively with the response in body
weight, BMI, waist, IGF1 SDS, and total and LDL-cholesterol.
Response in weight and BMI was greater in men than in women, whereas women showed greater
improvement in QoL than men. Patients with more severe GHD as assessed by lower GH-peaks and
more pituitary hormone deficiencies had a greater increase in IGF1 SDS. The increase in IGF1 SDS was
associated with a reduction in waist/hip ratio and an increase in weight, BMI, and triglycerides. There
was no correlation with other lipids, blood pressure, or glucose.
Conclusion: Our findings indicate that baseline and 24 months, IGF1 and its degree of increase during
GH replacement were more important than stimulated peak GH to predict the phenotypic response.
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Introduction
Severe GH deficiency (GHD) in adults causes an
impairment of quality of life (QoL) (1, 2), abnormal
body composition (3, 4, 5), and adverse cardiovascular
risk factors (6) that may contribute to the twofold
increase in mortality observed in patients with
hypopituitarism and not receiving GH replacement
therapy (7, 8). In children with GHD, the growth
velocity serves as a biological marker, which has led to a
prediction model for GH responsiveness in children (9).
In adults, however, the features of GHD are not
pathognomonic for the condition. Thus, endocrinolo-
gists evaluating adults have to rely upon biochemical
assessment by a provocative test to identify patients with
severe GHD (10). Furthermore, the response to GH
replacement is assessed by surrogate markers such as
phenotypic features, QoL evaluation, and measurement
of insulin-like growth factor 1 (IGF1) (11).
Clinicians prescribing GH to patients with GHD wish
to know which patients are most likely to respond to GH
with a measurable improvement, i.e. whether the tests
used for the diagnosis of GHD before treatment is started
can help predict those who will experience the best
clinical benefit from replacement. A few prediction
models have been presented (12, 13, 14), one of which
indicated that gender, body height, baseline lean body
mass, and serum insulin levels were the major clinical
predictors (12). It is well known that the response to GH
treatment is highly individual, and it is therefore of
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clinical interest to determine whether clinical variables
measured at the time of GHD diagnosis and during GH
replacement can suggest which patients may ultimately
respond better in the long-term.
In our previous studies we showed that even
hypopituitary patients with severe GHD, defined as a
GH-peak%3 mg/l at diagnostic testing, demonstrated a
relationship between phenotype and the degree of GH
severity (15, 16). We now investigate whether the
severity of GHD defined as i) GH-peak on stimulation
tests (insulin tolerance test (ITT), arginine, and
glucagon) (17, 18), ii) number of additional pituitary
deficits (19), or iii) baseline IGF1 SDS had an impact on
the response to GH replacement. We further explored
whether iv) the level of IGF1 SDS after 24 months of GH
replacement or v) the change (D) of IGF1 SDS from
baseline to 24 months was related to the phenotypic
response to GH treatment.
Materials and methods
KIMS (Pfizer International Metabolic Database), a
long-term safety and outcome study of GH replacement
therapy in adults, represents a large pharmaco-
epidemiological survey initiated in 1994 (20). In this
database, GH stimulation tests are reported in a
standardized fashion along with baseline and follow-
up data on BMI, waist circumference, waist:hip ratio,
blood glucose, HbA1c, systolic and diastolic blood
pressure, and QoL measured by QoL–Assessment of
Growth Hormone Deficiency in Adults score
(QoL-AGHDA) (21). Serum samples were analyzed
centrally for IGF1 levels and serum lipids (total
cholesterol, LDL-cholesterol, HDL-cholesterol, and tri-
glycerides) (22). The GH levels were measured using the
available assay at each investigator’s institution. We
previously analyzed serum GH concentrations in
relation to date of entry into the database and
demonstrated that there was no time-dependent trend
(15). Between 1994 and October 1997, measurements
of serum IGF1 were performed at Kabi Pharmacia
(Stockholm, Sweden), and thereafter at Sahlgrenska
University Hospital (Gothenburg, Sweden), using the
following assay methods: until November 2002, RIA
after acid/ethanol precipitation of IGF-binding proteins
(Nichols Institute Diagnostic, San Juan Capistrano, CA,
USA); until September 2006, chemiluminescence
immunoassay (Nichols Advantage System); and after
September 2006, Immulite 2500 (DPC Siemens,
Erlangen, Germany) (23). Intra-assay, inter-assay, and
total CV were!9% in the concentration range of 125–
1046 mg/l. The assay detection limit was 13.5 mg/l.
Age- and gender-specific reference ranges were used to
calculate an IGF1 SDS for each patient (15, 24, 25).
Serum total cholesterol, HDL-cholesterol, and triglycer-
ides were measured centrally by standardized methods
(26). Serum LDL-cholesterol was calculated according
to the Friedewald formula (27). Waist and hip
measurements were conducted according to KIMS
Guidelines (28) circulated to all participating
physicians, and BMI was calculated as body weight
(kg)/height (m2).
The patient cohort was obtained from KIMS, which
had 13 600 adult patients with GHD as of December
2008. Patients were included in this study if they were
naı¨ve (no GH treatment before entry), or semi-naı¨ve
(not on GH for at least 6 months). Only patients whose
diagnosis of GHD was based upon an ITT (nZ1096),
arginine stimulation test (AST; nZ400), and/or
glucagon stimulation test (GST; nZ256) were included.
Tests were performed within 1 year before or up to
1 month after entry into KIMS with peak GH%5.0 mg/l.
In patients with more than one accepted test, the
highest response was used in the analyses.
Other criteria included BMI !50 kg/m2, IGF1 SDS
!2 at baseline, and GH replacement therapy for
24 months with reported visits at baseline, 12, and 24
months. These criteria yielded a cohort of 1752
patients (881 women, 50%). To determine whether
treatment response could be predicted by the severity of
GHD, the patients were divided before the analysis into
three groups with roughly equal numbers of subjects
(tertiles). This resulted in three groups with
the following ranges of GH-peaks: very severe,
0–0.29 mg/l; severe, 0.3–0.8 mg/l; and moderate,
0.81–5.0 mg/l. The cut-offs were not decided arbitrarily
but driven by the data in order to obtain approximately
equal group sizes (Table 1). In addition, patients were
also grouped according to four prespecified IGF1
SDS ranges (!K2.0, K2.0 to K1.0, K1 to 0, and
0 to 2; Table 2).
Comparisons were made between the sub-groups at
12 and 24 months of replacement with GH for the
following available variables: BMI, cholesterol (total,
LDL, and HDL), triglycerides, waist circumference,
waist/hip ratio, blood glucose, HbA1c, systolic and
diastolic blood pressure, and QoL. QoL was determined
using the QoL-AGHDA questionnaire (21), where a
higher score denotes a poorer QoL and a decrease in
score thus indicates improvement.
The responses in IGF1 SDS and GH sensitivity at
12 months were evaluated as predictors for the
subsequent phenotypic response at 24 months. GH
sensitivity was calculated as the change in IGF1
concentration from baseline to 12 months divided by
the administered total amount of GH in milligrams
during the first 12 months of treatment. Furthermore,
associations between the variables at 24 months were
analyzed using bivariate correlation analyses.
Additional analyses were performed to assess for gender
difference and evaluate the impact of oral estrogens as
well as for use of lipid and glucose-lowering drugs.
Finally, data were also analyzed using a cut-off of 3 mg/l
by ITT only according to GRS gold standard for
diagnosing severe adult GHD (17).
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Statistical analysis
Parametric tests were used, such as independent and
paired samples t-tests and one-way ANOVA, in some
cases with post-hoc tests using the least significant
difference (LSD) correction. In correlation analyses
Pearson’s method was used. When nominal data were
tested, c2 tests and Fisher’s exact tests were utilized.
Additionally, because of very complex relationships and
interdependence between clinical characteristics and
response to GH, a path analysis (29) was performed.
In the path analysis, indirect effects from exogenous
and endogenous variables were measured by path
coefficients that are equal to and can be interpreted in
the same way as the standardized b coefficients
(K1%b%1) gained in multiple regression analyses.
Direct effect from exogenous variables was measured by
simple Pearsonian correlation coefficients. The total effect
was in each case the sum of direct (direct arrows between
boxes in Fig. 1) and indirect effects (e.g. an arrow from the
variable in question via another arrow through a second
variable to the response). When calculating total effects,
the indirect effects of variables, path coefficients, along a
path were thus multiplied and added to the direct
effect. The absolute size of the total effect mirrored the
relative importance of each independent (exogenous or
endogenous) variable. In the path analyses, only
variables with significant coefficients were used.
In the full model on the dependent variable (change
in IGF1 SDS (DIGF1 SDS) after 24 months of GH
replacement), direct influences were found from age at
KIMS entry, gender, and additional pituitary deficits,
and the exogenous variables were proposed to influence
the intermediary, endogenous variables GH-peak, and
IGF1 at baseline, that in turn were supposed to
influence GH dose and DIGF1 SDS.
The standard statistical package (SPSS) for Windows,
V20.0 (SPSS, Inc.) was utilized. Data are presented
as meanGS.D. Statistical significance was considered
if P!0.05.
Results
Baseline characteristics according to
GH-peak tertiles, IGF1 subgroups, and
additional pituitary deficiencies
At baseline before commencement of GH replacement,
there were more females (59%) in the group with
GH-peak response between 0.8 and 5.0 mg/l compared
with the two other groups (44 and 49% respectively)
(P!0.001; Table 1). The gender difference was opposite
for IGF1 levels; proportionally more women had an
IGF1 below K2 SDS (56%) or between K2 and K1
SDS (50%) compared with the higher IGF1 subgroups
(42 and 43%) (P!0.001; Table 2).
Table 1 Baseline characteristics of the GH-deficient patients grouped according to severity of GHD by GH-peak tertiles.
Severity of GHD: groups based on GH-peak
Severe Moderate Mild P!a
Number of patients 621 575 556
GH-peak (mg/l) 0–0.3 0.3–0.8 0.8–5
Gender: females (%, n) 44 (272) 49 (279) 59 (330) 0.001
Females using estrogen (%, n) 49 (133) 46 (129) 38 (126) 0.020
Lipid lowering drugs (%, n) 27 (72) 20 (56) 17 (56) 0.010
Childhood onset (%) 18 17 14 NS
Number of additional pituitary deficiencies (%)
Isolated GHD 3.5 10.6 22.3
1 10.5 17.9 27.9
2 15.2 19.5 21.4
3 45.5 34.7 22.1
4 25.3 17.2 6.3 0.001
Primary etiologyb (%)
Nonfunctioning pituitary adenoma 31.2 28.2 27.5 NS
Secreting pituitary adenoma 23.8 25.2 27.2 NS
Other sellar tumors 4.7 5.9 3.8 NS
Craniopharyngioma 12.7 10.6 3.8 0.001
Extrasellar tumor 3.1 4.9 5.9 NS
Idiopathic GHD 12.1 11.0 11.3 NS
Malignancy treatment 0.3 0.9 2.3 0.004
Traumatic brain injury 1.8 2.3 2.2 NS
Other 10.3 11.1 16.0 0.007
Age at pituitary disease onset (years, meanGS.D.) 36.2G17.3 36.1G17.1 36.1G16.3 NS
Age at GHD diagnosis (years, meanGS.D.) 43.8G16.7 42.2G16.2 41.4G15.4 0.036
Age at KIMS start (years, meanGS.D.) 46.6G14.2 44.8G14.0 43.4G13.8 0.001
aOver-all, tests were based on one-way ANOVA and Fisher’s exact test.
bAccording to the KIMS Classification List (reference: Go´th M, Hubina E & Korbonits M. Aetiology and demography of adult growth hormone deficiency.
In Growth Hormone Deficiency in Adults: 10 Years of KIMS, pp 75–82. Eds R Abs & U Feldt-Rasmussen. Oxford PharmaGenesis, 2004).
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Table 2 Baseline characteristics of the GH-deficient patients grouped according to prespecified IGF1 SDS values.
Severity of GHD: groups based on IGF1 SDS at baseline
1 2 3 4 P!a
Number of patients 741 457 372 182
IGF1 SDS !K2 K2 toK1 K1 to 0 0 to 2
Gender: females (%, n) 56 (417) 50 (227) 43 (160) 42 (77) 0.001
Childhood onset (%) 32.1 7.4 4.6 2.7 0.001
Number of additional pituitary deficiencies (%)
Isolated GHD 10.0 10.3 15.3 15.9
1 13.7 19.9 22.3 26.4
2 16.0 21.7 21.2 15.9
3 39.6 31.9 30.1 29.1
4 20.7 16.2 11.0 12.6 0.001
Primary etiologyb (%)
Nonfunctioning pituitary adenoma 18.5 38.5 36.6 33.0 0.001
Secreting pituitary adenoma 21.3 25.6 28.0 35.7 0.001
Other sellar tumors 6.2 4.4 2.2 5.5 0.025
Craniopharyngioma 11.5 7.0 8.6 6.6 0.031
Extrasellar tumor 5.7 4.4 3.2 3.3 NS
Idiopathic GHD 19.7 5.0 5.9 5.5 0.001
Malignancy treatment 0.7 1.5 1.9 0.5 NS
Traumatic brain injury 2.2 1.8 2.4 1.6 NS
Other 14.3 11.8 11.3 8.2 NS
Age at pituitary disease onset (years, meanGS.D.) 28.3G16.7 39.9G15.4 42.6G14 44.8G13.4 0.001
Age at GHD diagnosis (years, meanGS.D.) 35.8G17.4 46G13.9 47.8G12.8 50.2G11.8 0.001
Age at KIMS start (years, meanGS.D.) 39.8G14.3 47.6G13.4 49G12.2 51.5G11.2 0.001
aOver-all, tests were based on one-way ANOVA and c2. P values indicate ‘over-all’ difference.
bAccording to the KIMS Classification List (reference: Go´th M, Hubina E & Korbonits M. Aetiology and demography of adult growth hormone deficiency.
In Growth Hormone Deficiency in Adults: 10 Years of KIMS, pp 75–82. Eds R Abs & U Feldt-Rasmussen. Oxford PharmaGenesis, 2004).
Age at KIMS
entry
GH dose
∆ IGF1 SDS
Number of
pituitary deficiency Gender
GH-peak IGF1 SDS at
baseline
–0.05
0.06 –0.08
–0.64
–0.21
–0.12
0.42
0.18
0.13
0.16 –0.13
0.08
–0.11
–0.38
–0.04
–0.36
0.23
Figure 1 Path analysis of the complex interrelations between GH dose at 24 months. Baseline variables and change in IGF1 SDS from
baseline to 24 months. Numbers in the figure represent path coefficients (b). The total effect from the variables in the model was accounted
for by IGF1 SDS at baseline (K0.67), age (K0.39), additional pituitary hormone deficiencies (0.29), GH-peak at stimulation test (K0.19),
GH dose at 24 months (0.08), and gender (0.05).
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Women were more likely than men to have no, one,
or two other pituitary deficiencies (53, 58, and 55%
respectively), compared with three or four additional
deficiencies (43 and 49%) (P!0.001; data not shown).
Among the women, 44% (nZ388) used estrogens
(most of them orally), with a lower proportion among
the patients with the highest GH-peak (Table 1).
A number of patients (132, 0.5%) used glucose-
lowering drugs, distributed evenly among the sub-
groups. However, among the 370 (17%) patients taking
lipid-lowering drugs, a lower proportion was found in
the group with the highest GH-peak (Table 1). There
were significantly more craniopharyngiomas in the
groups with the lowest GH-peak and IGF1 SDS and in
the group with most additional deficiencies (Tables 1
and 2). Idiopathic GHD was more often seen in isolated
GHD, and more often had lower IGF1 SDS (P!0.001)
but similar GH-peak. The other diagnoses were largely
similar among the groups. Age at diagnosis of GHD and
at KIMS start was higher in the very severe group, in the
0–2 SDS IGF1 group, and in the group with fewer
additional pituitary hormone deficiencies. Childhood
onset GHD was more prevalent in isolated GHD and in
the subgroup with lower IGF1 SDS but was similarly
distributed across the GH-peak groups (Tables 1 and 2).
GH-peak and phenotypic response to GH
replacement
Comparisons of the GH-peak groups (very severe, severe,
and moderate GHD) in relation to change in phenotypic
features after 24 months of GH replacement are shown
in Table 3. Compared with baseline, significant
differences between the three groups were demonstrated
after 2 years of treatment for HDL-cholesterol, which
increased slightly more on replacement (0.05 mmol/l) in
the very severe group compared with the severe group
(P!0.05), which in turn showed no change. Body
weight and waist circumference decreased more in the
very severe group at 12 months (data not shown), but
this difference between groups was not sustained at
24 months. QoL-AGHDA scores at both 12 (data not
shown) and 24 months (Table 3) improved less in the
very severe group (K3.7G5.5) compared with both the
severe (K4.8G6.0, P!0.009) and the moderate group
(K4.8G6.5, PZ0.013). The change in IGF1 SDS at
both 12 and 24 months was more pronounced in the
very severe GH-peak group and differed between all three
groups, with a mean increase of 2.7G1.7 in the very
severe, 2.3G1.6 in the severe, and 1.7G1.5 in
the moderate GH-peak group respectively (P!0.001).
The lower the GH-peak, the more pronounced was the
increase in IGF1 SDS, but the less pronounced
the improvement in QoL. These associations were seen
in the background of the very severe group having more
men than the other two groups, and patients with
craniopharyngioma and nonfunctioning pituitary ade-
noma, while the mean age at diagnosis of the pituitary
disease as well as at start in KIMS was higher (Table 1).Ta
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Thus, a low GH-peak predicted a good IGF1 response but
with a poorer QoL outcome and no significant differences
in any of the other phenotypic features. Reanalyses
using a cut-off of 3 mg/l showed similar results to the
analyses mentioned above (data not shown).
IGF1 SDS at baseline and phenotypic response
to GH replacement
Except for a minor relationship between blood pressure,
HbA1c, lipids, and additional pituitary hormone
deficiencies at 24 months, only DIGF1 SDS at 12 and
24 months had a consistent association with IGF1 SDS
at baseline (data not shown). Table 4 shows the
comparison between the four IGF1 subgroups at
baseline (subgroup 1Zthe lowest IGF1 SDS) regarding
changes in phenotypic features after 24 months.
Significantly larger increases were demonstrated in
the lowest IGF1 SDS subgroup for body weight (group 1
vs groups 2, 3, and 4, P!0.001) and BMI (group 1 vs
groups 2 and 4, P!0.006), while larger decrements
were seen in the higher IGF1 SDS subgroup for
total cholesterol (group 1 vs 3, P!0.014) and
triglycerides (group 1 vs 3 and group 2 vs 3, P!0.01).
Lower IGF1 SDS at baseline was associated with a more
pronounced increase in weight (rZK0.09, P!0.0001),
BMI (rZK0.08, P!0.01), total cholesterol (rZK0.08,
P!0.01), and triglycerides (rZK0.07, P!0.05). The
DIGF1 SDS differed among all groups, with a larger
change seen in patients with lower IGF1 SDS at baseline
(all comparisons P!0.001). In a subgroup analysis,
women using estrogens (nZ388, 44%) had lower IGF1
levels at baseline and responded with a higher DIGF1.
Most of these differences between the groups had also
been seen after 12 months (data not shown) and were
thus sustained through 24 months of GH replacement.
These associations were observed with the background
of the lowest IGF1 group (!K2 SDS) containing a
higher proportion of patients who were female, had
childhood onset pituitary disease, were younger at
pituitary diagnosis and KIMS start, and more frequently
had craniopharyngiomas, additional pituitary insuffi-
ciencies, and idiopathic GHD (Table 2).
Number of additional pituitary insufficiencies
at baseline and phenotypic response to GH
replacement
There were statistically significant differences between
groups characterized by the number of additional
pituitary hormone deficiencies, in terms of gender,
age, etiology, onset of disease, age at onset of the
pituitary disease, and entrance into KIMS (data not
shown). Waist circumference showed a more marked
decrease in the group without additional deficiencies
compared with the others (P!0.04), and increasing
number of deficiencies resulted in a larger increment of
IGF1 SDS. No other associations were identified.Ta
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Other baseline features influencing the
phenotypic response to GH replacement
Patients with a high body weight atbaseline decreased their
weight more than leaner subjects (rZK0.10, P!0.0001)
and age was also negativelycorrelated tothe response toGH
in weight (rZK0.15, P!0.0001), BMI (rZK0.12,
P!0.0001), waist circumference (rZK0.06, P!0.05),
total cholesterol (rZK0.08, P!0.01), and LDL-choles-
terol (rZK0.09, P!0.01) (data not shown).
Compared with men, women decreased weight
(P!0.05) and BMI (P!0.05) to a lesser degree but
increased QoL more (P!0.01). The GH-peak and
number of additional hormone deficiencies predicted
only the DIGF1 SDS (rZK0.23 and 0.18 respectively
P!0.0001; data not shown).
Prediction of GH response at 24 months by
first year response to GH
The GH sensitivity in the whole cohort of patients
demonstrated a bell-shaped distribution. GH sensitivity
predicted the phenotypic response from 12 to 24 months
in diastolic blood pressure (rZK0.09, P!0.001),
total cholesterol (rZK0.07, P!0.05), and IGF1 SDS
(rZK0.31, P!0.0001). IGF1 SDS at 12 months
predicted the response in waist circumference
(rZ0.07, P!0.05) and total cholesterol (rZK0.06,
P!0.05), while change in IGF1 SDS within the first year
predicted the change of BMI (rZ0.06, P!0.05), blood
glucose (rZK0.10, P!0.01), and the change of IGF1
SDS (rZK0.31, P!0.0001). The negative association
between peak GH and baseline and DIGF1, respectively,
was slightly attenuated by controlling for estrogen use,
but still highly significant (P!0.00001; data not shown).
Association between outcomes of 24 months’
GH replacement
DIGF1 SDS correlated positively with the change in
weight (rZ0.13, P!0.0001; Fig. 2, Table 5), BMI
(rZ0.11, P!0.0001), and triglycerides (rZ0.06,
P!0.05), and negatively with waist/hip ratio
(rZK0.07, P!0.05). In other words, an increase in
IGF1 SDS after 24 months was associated with a
reduction in waist/hip ratio. IGF1 SDS at 24 months
was negatively correlated with a change in waist/hip
ratio (rZK0.06, P!0.05), change in QoL-AGHDA
score (rZK0.09, P!0.01; in men NS; in women:
rZK0.17, P!0.001), and change in total cholesterol
(rZK0.06, P!0.05), the latter of which disappeared
when controlling for use of lipid lowering drugs.
Path analysis of the change of IGF1 SDS
from baseline to 24 months, DIGF1 SDS
Path analysis confirmed the complexity of interrelations
between the variables involved in the change of IGF1
SDS in response to GH (Fig. 1, Table 5). IGF1 SDS at
baseline had the most important influence on DIGF1
SDS (bZK0.64) and this influence was further
strengthened to K0.67, through the indirect effect via
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Figure 2 Scattergrams showing change (D) in (A) body weight and
(B) waist hip ratio vs change in IGF1 SDS after 24 months of GH
replacement therapy of adult patients with GHD and change (C) in
body weight vs age at KIMS entry.
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GH dose. Thus, patients with a low-basal IGF1 SDS had
a greater DIGF1 SDS at 24 months than patients with
higher IGF1 SDS levels.
Age at KIMS start had a direct influence on DIGF1
SDS (rZK0.12). This effect was strengthened by the
paths via IGF1 SDS at baseline and GH dose and
weakened somewhat by the path via the number of
additional deficits (rZ0.06). The total effect of age was
K0.41, i.e. with increasing age, IGF1 SDS changed less
under GH replacement therapy.
The number of pituitary hormone deficits in addition
to GHD had a direct effect on DIGF1 SDS (rZ0.18). The
total effect was 0.32, reached through the paths via all
the intermediary predictors.
Gender by itself did not have a significant correlation
with DIGF1 SDS. The total influence of gender was thus
weak (0.05) and reached through paths via all inter-
mediary predictors but weakened by the reciprocal
correlationwith the numberofadditionalpituitarydeficits.
The GH-peak had an indirect path to DIGF1 SDS with
a low b coefficient (K0.04), but the total effect was
enforced by another indirect effect via basal IGF1 SDS
and therefore amounted to K0.19.
GH dose at 24 months was at the last position in the
chain of predictors, and thus had only one path to
DIGF1 SDS with a weak b coefficient of 0.08 (Fig. 1).
Discussion
The response to GH replacement in adults is less
predictable than in children and includes many
Table 5 Significant and borderline significant correlation coefficients between change in a number of variables between baseline (BL)
and 24 months (24M) of GH replacement and stimulated GH-peak, additional hormone deficiencies, IGF1 SDS at baseline, and IGF1 SDS
at 24 months. IGF1 SDS, GH dose at 24 months, and GH sensitivity at 24 months. The correlation between IGF1 at 24 months and
cholesterol disappeared after controlling for use of lipid lowering drugs, while all other correlations remained when controlling for this and for
glucose-lowering drugs.
Change 24M – BL GH-peak
Additional
pituitary
hormone
deficits
IGF1 at
baseline
IGF1 at 24
months DIGF1
Dose at 24
months GH sensitivity
Body weight (kg)
r K0.091 0.129 0.08
P! 0.001 0.001 0.002
BMI (kg/m2)
r K0.075 0.113 0.084
P! 0.002 0.001 0.001
Waist (cm)
r K0.053
P! 0.057
Waist/Hip ratio
r K0.061 K0.067
P! 0.028 0.017
Systolic BP (mm Hg)
r
P!
Diastolic BP (mm Hg)
r 0.043
P! 0.087
B-glucose (mmol/l)
r 0.064
P! 0.068
HbA1c (%)
r 0.052
P! 0.074
Cholesterol (mmol/l)
r K0.081 K0.061
P! 0.005 0.033
HDL (mmol/l)
r K0.05
P! 0.078
LDL (mmol/l)
r
P!
Triglycerides (mmol/l)
r K0.069 0.059
P! 0.015 0.038
QoL-AGHDA
r K0.054 K0.057 K0.094
P! 0.072 0.058 0.003
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variables such as changes in body composition, QoL,
and blood lipids (30, 31), and many confounders have
to be taken into account (32, 33). Prediction models in
children with short stature incorporated data from
a very large number of patients in the calculations
(9, 34, 35). In contrast, prediction of GH response has
been described in only a limited number of adults with
GHD (12, 13, 14), and we therefore explored predictors
of response using the large KIMS database (20).
The original and follow-up consensus statements of
the Growth Hormone Research Society identified ITT as
a gold standard simulation test for diagnosing severe
GHD (peak GH !3 mg/l) in adults (17, 18). Toogood
et al. (19) demonstrated that the severity of hypopitui-
tarism as indicated by the number of anterior pituitary
hormone deficits was associated with the GH response
to ITT. This observation was substantiated in our
previous studies of larger patient cohorts with severe
GHD based on peak GH of !3 mg/l during ITT, AST,
or GST stimulation tests (15, 16). In our selection of
the patient cohort for the current study, we included
those who had a GHD diagnosis confirmed by any of the
three tests, allowing a cut-off !5 mg/l in order not to
exclude young adult patients, whose cut-off levels are
considered to be higher than in older adults (36). The
cut-off of !5 mg/l has furthermore been demonstrated
to provide a more optimal sensitivity and precision in
receiver operating curves (ROC) curves distinguishing
hypopituitary patients from controls (37). Nevertheless,
we performed analyses using the classical cut-off of
!3 mg/l which confirmed our results.
In a prior study on patients with severe GHD, the
age at which the patient was tested did not affect
the performance of the ITT, AST, and GST (16). This
suggested that the impact of pituitary disease overrode
the subtle changes that occur in the regulation of GH
secretion with aging and need not be taken into account
when diagnosing GHD in this clinical scenario (16, 38).
On the other hand, in the current study on hypopitui-
tary patients with GHD, older age negatively predicted
the response to GH in weight, BMI, waist circumference,
and total and LDL-cholesterol, in keeping with a
previous description of GH replacement in the elderly
(39), while others have identified elderly GHD patients
as a GH-sensitive group (40, 41).
Obesity has consistently been shown to inhibit
spontaneous GH secretion and all dynamic function
tests that have been studied – the greater the BMI, the
less GH produced (16, 33, 37, 42). Concerns have
therefore been raised that obesity may compromise a
reliable diagnosis of GHD because the GH response to
stimulation tests will be attenuated. It is also possible
that the benefit of GH replacement might be hampered
by obesity. The current study was therefore reassuring
that patients who were obese at baseline decreased
their weight more than patients with lower body
weight. Conversely, body weight and BMI both increased
with increasing increment of IGF1 SDS. However, waist
circumference and waist/hip ratio decreased with
increasing increment of IGF1 SDS, suggesting that GH
replacement therapy increased muscle mass rather
than fat mass. Another possibility may be a weight
gain due to water and sodium retention through renal
effects of GH (43). A more precise evaluation of body
composition was, however, unavailable in KIMS to test
this hypothesis.
Serum IGF1 has a limited role in the diagnosis of GHD
in adults (10), although the levels are highly influenced
by GH status and there are correlations between the
two (15). In our current study, IGF1 SDS was a strong
predictor of the response to GH replacement, in
agreement with some previous reports (44), but in
disagreement with others (12, 13, 14). We also found
that women using estrogens had lower IGF1 levels at
baseline but responded better in terms of DIGF1.
A recent study developed accurate mathematical
models to predict GH responsiveness in GHD adults
and found gender, body height, baseline lean body mass,
and serum insulin levels as the major clinical predictors
(12). We were not able to test this model, since
measurements of lean body mass and insulin were not
available in the KIMS database.
There are a number of limitations to our study.
Unlike IGF1, GH was measured in each individual
laboratory, which was a possible confounder of the
results of GH-peaks. GH measurements are generally
not very well standardized between methods and
laboratories (45), and the period for entrance of patients
into the KIMS database spanned more than 15 years.
However, we have previously detected no variation
in the GH-peaks over time (15). Furthermore, the size
of the study should theoretically eliminate or at least
diminish the influence from confounders and method
variation, but it cannot be excluded that the results
were partly affected by differences in GH measurements.
Although central IGF1 measurements is one of the
strengths of our study, it is worth mentioning that there
were a number of changes in the assay methods used,
which may also have influenced the results. Finally,
adjustment for changes in other hormone replacements
was not performed because of variability in the
accuracy of concomitant medication reporting.
In summary, the extent of hypopituitarism indi-
cated by the GH stimulation test peak and the number
of additional hormone deficiencies did not have an
independent impact on the response to GH but predicted
only the IGF1 SDS response. IGF1 at baseline predicted
the GH treatment response in weight, BMI, cholesterol,
and triglycerides; age predicted the response in body
weight, BMI, waist, and total and LDL-cholesterol,
while gender predicted the responsiveness in weight,
BMI, and QoL-AGHDA. In addition, the IGF1 response
to GH treatment from baseline to 24 months, as
well as the IGF1 SDS with 24 months of replacement,
was associated with a positive treatment effect on
weight, BMI, waist/hip ratio, and triglycerides, but not
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on other lipids, blood pressure, or blood glucose, and
with reduction in waist/hip, total cholesterol, and
QoL-AGHDA respectively.
In conclusion, our findings have indicated that IGF1
at baseline and at 24 months, as well as its change
during treatment, played a more important role than
peak GH to stimulation testing in predicting the
phenotypic response to GH replacement. However, the
clinical implications of these observations remain to
be proven in future studies.
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